Nuvalent, Inc.·4

Jul 1, 4:30 PM ET

Noci Darlene 4

4 · Nuvalent, Inc. · Filed Jul 1, 2026

Research Summary

AI-generated summary of this filing

Updated

Nuvalent (NUVL) CDO Darlene Noci Exercises Options and Sells Shares

What Happened

  • Darlene Noci, Chief Development Officer of Nuvalent (NUVL), exercised options on 5,500 shares on 2026-06-29 at a strike price of $27.85 (cost $153,175) and sold those 5,500 shares the same day in the open market for weighted-average proceeds of $679,305. The filing also records a related derivative conversion/disposition for 5,500 shares at $0.00 (reflecting the option conversion/settlement).

Key Details

  • Transaction date: June 29, 2026; Form 4 filed July 1, 2026 (appears timely).
  • Exercise: 5,500 shares acquired at $27.85 each — total cost $153,175.
  • Sale: 5,500 shares sold in multiple trades for a weighted-average price of $123.51 — total proceeds $679,305 (prices ranged $123.47–$123.56).
  • Derivative line: 5,500 shares recorded as disposed at $0.00 (reflects option conversion/settlement).
  • Footnotes: Transactions were made under a Rule 10b5-1 trading plan adopted Nov 18, 2024 (F1). The reported sale price is a weighted average; the filer can provide per-trade prices on request (F2). Underlying options vest monthly over four years beginning Jan 6, 2023 (F3).
  • Shares owned after transaction: Not stated in the provided filing excerpt.

Context

  • This was an exercise-and-sell on the same day (effectively a cashless exercise followed by a market sale). The sale was executed under a pre-established 10b5-1 plan, which schedules trades in advance and is commonly used to avoid trading on material nonpublic information.
  • Sales by executives are often routine (e.g., option exercises, tax/portfolio management). The filing shows gross proceeds of $679,305 vs. $153,175 in exercise cost (about $526,130 difference) before taxes and fees.

Insider Transaction Report

Form 4
Period: 2026-06-29
Noci Darlene
Chief Development Officer
Transactions
  • Exercise/Conversion

    Class A Common Stock

    [F1]
    2026-06-29$27.85/sh+5,500$153,17563,617 total
  • Sale

    Class A Common Stock

    [F1][F2]
    2026-06-29$123.51/sh5,500$679,30558,117 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F3]
    2026-06-295,50081,329 total
    Exercise: $27.85Exp: 2033-01-06Class A Common Stock (5,500 underlying)
Footnotes (3)
  • [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
  • [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.47 to $123.56, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price.
  • [F3]The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
Signature
/s/ Nathan McConarty, attorney-in-fact|2026-07-01

Documents

1 file
  • 4
    ownership.xmlPrimary

    4